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KAT2A/KAT2B-targeted acetylome reveals a role
for PLK4 acetylation in preventing centrosome
ampliﬁcation
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Lysine acetylation is a widespread post-translational modiﬁcation regulating various biological
processes. To characterize cellular functions of the human lysine acetyltransferases KAT2A
(GCN5) and KAT2B (PCAF), we determined their acetylome by shotgun proteomics. One of
the newly identiﬁed KAT2A/2B substrate is polo-like kinase 4 (PLK4), a key regulator of
centrosome duplication. We demonstrate that KAT2A/2B acetylate the PLK4 kinase domain
on residues K45 and K46. Molecular dynamics modelling suggests that K45/K46 acetylation
impairs kinase activity by shifting the kinase to an inactive conformation. Accordingly, PLK4
activity is reduced upon in vitro acetylation of its kinase domain. Moreover, the over-
expression of the PLK4 K45R/K46R mutant in cells does not lead to centrosome over-
ampliﬁcation, as observed with wild-type PLK4. We also ﬁnd that impairing KAT2A/2B-
acetyltransferase activity results in diminished phosphorylation of PLK4 and in excess cen-
trosome numbers in cells. Overall, our study identiﬁes the global human KAT2A/2B acet-
ylome and uncovers that KAT2A/2B acetylation of PLK4 prevents centrosome ampliﬁcation.
DOI: 10.1038/ncomms13227 OPEN
1 Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire (IGBMC), 67404 Illkirch, France. 2 Centre National de la Recherche Scientiﬁque, UMR7104,
67404 Illkirch, France. 3 Institut National de la Sante´ et de la Recherche Me´dicale, U964, 67404 Illkirch, France. 4 Universite´ de Strasbourg, 67404 Illkirch,
France. 5 Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK. 6 Swiss Institute for Experimental Cancer
Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), CH-1015 Lausanne, Switzerland. * These authors
contributed equally to this work. w Present addresses: Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan (C.G.). Correspondence and
requests for materials should be addressed to P.G. (email: pierre.gonczy@epﬂ.ch) or to L.T. (email: laszlo@igbmc.fr).
NATURE COMMUNICATIONS | 7:13227 | DOI: 10.1038/ncomms13227 |www.nature.com/naturecommunications 1
L
ysine (K) acetylation has emerged as a widespread post-
translational modiﬁcation that is conserved from
prokaryotes to eukaryotes, and which regulates various
biological processes1–6. Lysine acetylation can modify the charge
of a given protein and/or create docking sites for other proteins
that may alter their function7. A prime example of the
signiﬁcance of such modiﬁcation is the acetylation of histones,
which plays an essential role in transcriptional activation,
DNA replication and repair8. Remarkably, in addition, lysine
acetylation also targets thousands of non-histone proteins1,2,
but the functional relevance of the vast majority of these
modiﬁcations is not known.
Lysine acetylation is catalysed by K acetyltransferases (KATs;
formerly histone acetyltransferases, HATs), which transfer the
acetyl group of acetyl-CoA to the epsilon-amino group of internal
lysine residues9. Whereas B6,000 proteins have been reported
to be acetylated in human cells (Phosphositeplus10), only B20
KATs have been identiﬁed to date (reviewed in ref. 11),
suggesting that each KAT could acetylate several hundred
targets. Thus, it is important to identify the speciﬁc subset of
proteins acetylated by each individual KAT. The human KAT2A
(GCN5) and its B70% identical paralogue KAT2B (PCAF)
are known to play a role in diverse biological processes,
such as chromatin remodelling, transcriptional regulation,
DNA replication, DNA repair, cell cycle progression and
cell death12–18. KAT2A/2B are mainly studied as HATs that
acetylate preferentially histone H3 and to a lesser extent H4
(ref. 19 and references therein), leading to changes in chromatin
structure. However, KAT2A/2B can also acetylate non-histone
targets, such as CDC6 and cyclin A to regulate the G1/S cell cycle
transition and mitosis13,14. While KAT2A/2B have been
implicated in given cellular processes, a comprehensive list of
their cellular targets has not yet been assembled, although the
identiﬁcation of such targets should provide more mechanistic
insights into their mode of action.
Metazoan KAT2A/2B function within several multiprotein
coactivator complexes, such as SAGA (Spt-Ada-GCN5 acetyl-
tranferase (AT) containing) and ATAC (Ada-Two-A-containing
complex)20–22. We have previously shown that ATAC controls
mitotic progression by acetylating cyclin A, and that impairing
the activity of KAT2A/2B leads to increased centrosome numbers
in mammalian cells14. However, the mechanisms underlying the
requirement of KAT2A/2B in regulating centrosome numbers
remained elusive.
Centrosomes consist of a pair centrioles surrounded by
pericentriolar material, from which microtubules are nucleated
in animal cells. Proliferating cells are typically born with two
centrioles, which duplicate once per cell cycle, starting towards
the G1/S transition. As a result, cells in S phase and thereafter
contain two pairs of centrioles, each within one centrosome. At
the G2/M transition, the two centrosomes separate to direct
bipolar spindle assembly during mitosis. Aberrant centrosome
number has dire consequences for cell division and genome
integrity, since too few centrosomes can lead to monopolar
spindle assembly and too many centrosomes to multipolar
spindle assembly23–25. Centrosome ampliﬁcation is frequently
observed in human cancer and has been proposed to contribute
to tumour progression23–25. Therefore, the precise regulation of
the number of centrosomes is fundamental for human health.
In metazoans, a key regulator of centrosome number is the
serine/threonine polo-like kinase 4 (PLK4)26,27. PLK4 depletion
results in failure of centriole formation, whereas its
overexpression leads to supernumerary centrioles26,27.
Therefore, PLK4 protein levels and kinase activity must be
tightly regulated. This is achieved in part by PLK4 protein
stability being regulated by auto-phosphorylation, which triggers
ubiquitin-mediated proteasomal degradation (reviewed in refs
28–30). Whereas the mechanisms regulating PLK4 activation,
protein ubiquitination and degradation have been clariﬁed, those
modulating PLK4 kinase activity remain elusive.
In this study, we have determined the KAT2A/2B-dependent
acetylome of human cells and identify 398 acetylated KAT2A/2B
target proteins involved in diverse cellular processes. Further-
more, our detailed analysis uncovers that KAT2A/2B-mediated
lysine acetylation of PLK4 negatively regulates its kinase activity
and thus keeps in check the number of centrosomes in human
cells, thereby contributing to the maintenance of genome
integrity.
Results
Characterization of the human KAT2A/2B-dependent acetylome.
To comprehensively identify proteins acetylated speciﬁcally
by endogenous KAT2A/2B (GCN5/PCAF), we performed a
large-scale unbiased screen using tandem mass spectrometry
(MS)-based shotgun proteomics, comparing acetylated proteins
in control cells and in cells in which KAT2A and KAT2B were
simultaneously knocked down. We used two stable HeLa cell lines
in which doxycycline (Dox) induces the expression of either a
control short-hairpin (sh) RNA (Tet-shCTRL) or a shRNA
targeting KAT2A (Tet-shKAT2A)14. In addition, KAT2B was
knocked down in the latter cell line by siRNA transfection
(Fig. 1a). The efﬁciency of KAT2A and KAT2B knockdown was
veriﬁed by western blot analysis (Fig. 1a) and further ascertained
by the decrease of histone H3 acetylation at position K9,
a well-known in vivo target of these KATs31 (Fig. 1a, lowest
panel). The redundant acetylation of H3K9 by other nuclear
KATs following the depletion of KAT2A/2B likely explains the
remaining signal in lane 5 of Fig. 1a.
The acetylated peptide pool was then identiﬁed either under
control conditions in ﬁve biological replicates or in the double
KAT2A/2B knockdown cells in three biological replicates, and
compared. Acetylated peptides and their corresponding proteins
that were detected solely in the control cells (in a minimum of 3/5
replicates), but not in the knockdown conditions, were considered
as potential targets of KAT2A/2B. This stringent cutoff led to the
identiﬁcation of 1,569 acetylated sites on 398 proteins (Fig. 1b
and Supplementary Data 1). Among these KAT2A/2B targets,
251 proteins (about 63%) were already found to be acetylated in
global acetylome screens (see the protein modiﬁcation resource:
PhosphositePlus10, Supplementary Fig. 1), validating our
approach. The analysis of amino-acid frequency surrounding
the identiﬁed acetylated lysines revealed enrichment for further
lysine residues, as compared with the frequency of residues
surrounding non-acetylated lysines (Fig. 1c and Supplementary
Data 1). This result suggests that the amino-acid composition
surrounding lysines inﬂuences the substrate speciﬁcity of
KAT2A/B, which preferentially acetylate lysine-rich regions of
proteins. This is in good agreement with previous reports
showing an enrichment of lysines residues surrounding
acetylated lysines in global human acetylome data sets1,32,33.
Gene ontology term analyses of the 398 non-histone proteins
identiﬁed here using Manteia34 indicated that the KAT2A/2B
acetylated proteins play a role in cellular functions in which
KAT2A/2B have already been implicated, including chromatin
remodelling, transcriptional regulation, DNA replication, DNA
repair, cell death and cell cycle progression (Fig. 1d,e and
Supplementary Data 1). Interestingly, the gene ontology term
analysis also suggested KAT2A/2B-dependent regulation of
novel pathways, such as actin-mediated cell contraction, protein
transport, phosphorylation and regulation of centrosome
duplication (Fig. 1d,e and Supplementary Data 1). Overall,
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Figure 1 | Identiﬁcation of the KAT2A- and KAT2B-dependent acetylome. (a) KAT2A/2B knockdown efﬁciency. Tetracycline (Tet) inducible stable HeLa
cell lines were used in which shRNAs either not targeting any endogenous transcript (Tet-shCtrl) or targeting KAT2A (Tet-shKAT2A) were expressed under
doxycycline (Dox) induction. In the Tet-shKAT2A cell line, a siRNA against KAT2B (K2B) was also transfected. The knockdown efﬁciency of KAT2A, KAT2B and
the acetylation of histone H3K9 was tested by western blot analyses. (b) In all, 398 potential KAT2A/2B acetylated protein targets were identiﬁed as being
present in control samples (3/5), but absent in all KAT2A/2B KD-depleted cell lysates. (c) Analysis of the frequency of amino acids surrounding the
acetylated lysines targeted by KAT2A and KAT2B, as compared with that of amino acids surrounding non-acetylated lysines. In all, 1,569 distinct ‘Ks’ from the
list of 398 proteins were used in this analysis, with 10 aa upstream ( 10 on the x axis) and 10 aa downstream (þ 10 on the x axis). The K itself (at position 0)
is not shown in these logos. A random selection of 5,243 sequences (K in the middle, 21 aa length, 0.05% of the total K) from the total human proteins was
used for the comparison. The overall height of the stack indicates the sequence conservation at that position, while the height of symbols within the stack
indicates the relative frequency of each amino acid at that position. Note that the y axes on the upper and lower graphs are different. (d) Gene ontology (GO)
term enrichment analysis for biological processes using Manteia34 of the 398 identiﬁed proteins. Pathways at a false discovery rate below 1% are represented.
The x axis represents the reverse P value obtained after GO term enrichment analysis in Manteia34. Txn,transcription. (e) Examples of proteins acetylated by
KAT2A/2B belonging to the same biological pathways targeted by KAT2A/2B (see GO term analysis in d).
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these ﬁndings indicate that the action of KAT2A/2B is more
widespread than previously suspected and uncover novel
processes by which these KAT2s might modulate cell physiology.
The kinase domain of PLK4 is acetylated by KAT2A and KAT2B.
To further analyse the KAT2A/2B-dependent acetylome, we
focused on centrosome duplication, a process in which a role for
lysine acetylation was not established before our study. Given that
PLK4 is one of the key regulators of centrosome duplication, and
as the acetylated lysine residues (K45/K46) are localized in the
PLK4 kinase domain (see tandem mass spectra of the acetylated
PLK4 peptide in Supplementary Data 1 and Supplementary
Fig. 2a), we set out to investigate the biological relevance of these
acetylations. Note that these two lysine residues are conserved in
PLK4 proteins from Drosophila to human (Fig. 2a), suggesting
functional relevance.
To test whether PLK4 can be acetylated by KAT2A or KAT2B
in vitro, we performed AT assays on recombinantly expressed
PLK4 kinase domain in the presence of acetyl-CoA and puriﬁed
recombinant human KAT2A or KAT2B (Fig. 2b). As a negative
control, we also expressed the recombinant catalytic mutants
(mut) of KAT2A and KAT2B. Histone H3 acetylation by
KAT2A/2B (ref. 35) was used as a positive control
(Supplementary Fig. 2b, lanes 5 and 11). Importantly, we found
that recombinant PLK4 kinase domain was acetylated in the
presence of puriﬁed KAT2A or KAT2B (Fig. 2b, lane 8 and 10).
By contrast, the kinase domain was not acetylated when the
catalytic dead double point mutant of KAT2A (ref. 36) (lane 9) or
KAT2B (lane 11) were used instead. Note, however, that the
double point mutant of KAT2B retained some residual
acetylation activity towards the histone octamer substrate
(Supplementary Fig. 2b, lane 12).
To further validate the acetylation of K45 and K46 residues
identiﬁed in the comprehensive proteomic analysis, in vitro AT
assays were performed on recombinant PLK4 kinase domain,
followed by tandem MS analysis (Supplementary Fig. 2c and
Fig. 2c). Lysines K45 and K46 were found to be acetylated
by KAT2A or KAT2B, as were another two lysines of the
ATP-binding site (K41 and K68), which were not identiﬁed in the
large-scale study. Note that the in vitro AT assay using puriﬁed
recombinant protein fragments may result in more sites than the
ones identiﬁed in cells on endogenous full-length PLK4 protein.
The above results together demonstrate that PLK4 can be
acetylated by KAT2A/2B on residues K45/K46 in its kinase
domain.
To further address whether PLK4 is acetylated in cells,
we have developed an antibody against a PLK4 peptide acetylated
on positions K45 and K46 (Supplementary Methods and
Supplementary Fig. 3a,b). When HEK293 cells were transfected
with expression vectors for Flag-KAT2A or Flag-KAT2B, we
detected an increase of the acetylated form of PLK4 (PLK4ac),
in particular on overexpression of Flag-KAT2B, but not of overall
PLK4 levels (Fig. 2d). Moreover, the anti-PLK4ac antibody
detected centrosomes in immunoﬂuorescence experiments, with
the signal being juxtaposed with that of antibodies directed
against the centriolar protein Centrin-2 (ref. 26; Fig. 2d, upper
panels). Importantly, the PLK4ac signal completely disappeared
when PLK4 was knocked down with siRNAs (lower panel),
demonstrating that the raised antibodies are speciﬁc to PLK4.
KAT2A/2B and PLK4ac co-localize at centrosomes. Because we
identiﬁed PLK4 as an acetylated target of KAT2A/2B, and since
PLK4 localizes to centrosomes26, we investigated whether KAT2A
or KAT2B also localize to centrosomes, and this across the cell
cycle. To this end, we conducted immunoﬂuorescence analyses
using antibodies raised against KAT2A, or against KAT2B,
together with antibodies against one of several centriolar proteins:
HsSAS-6 (ref. 37); Centrin-2 (ref. 38); CP110 (ref. 39); or else
PLK4ac. These experiments showed that both KAT2A and
KAT2B could indeed be detected at centrosomes (Fig. 3a).
We then sought to test when during the cell cycle such
centrosomal localization occurs, focusing our analysis on KAT2A.
This revealed that KAT2A, which is known to localize to the
nucleus in interphase and to spindle poles in mitosis14, localized
also to centrosomes, in particular in late G1 and around the G1/S
transition, coinciding with the onset of centriole formation
(Fig. 3b,c). PLK4 is enriched at centrosomes throughout the cell
cycle and is thought to be critical during late G1 and/or at the
G1/S transition to initiate centriole assembly40–42. In agreement
with the fact that PLK4 is acetylated by KAT2A/2B, we found that
the percentage of cells in which PLK4ac and KAT2A were both
present at centrosomes was maximal in late G1 and the G1/S
transition (Fig. 3d). These observations together suggest that
PLK4/PLK4ac and KAT2A/2B co-localize at centrosomes,
primarily during late G1 and early S phases.
We next addressed whether KAT2A and PLK4 could associate
in cells during late G1 and early S phases. To this end, we ﬁrst
synchronized HeLa Kyoto cells in G1/S using a double thymidine
block and then released them for given times before collection
(Fig. 3e). Whole-cell protein lysates (WCLs) were prepared and
the cell cycle proﬁle veriﬁed using the cell cycle progression
markers Cyclin E and PLK1 (refs 43,44; Fig. 3e). Using these
staged protein extracts, immunoprecipitation (IP) experiments
were carried out with anti-KAT2A antibodies or with
control antibodies (Fig. 3f). Western blot analysis using
anti-PLK4 and anti-KAT2A antibodies showed that KAT2A
co-immunoprecipitated PLK4 mainly during the G1/S transition
and S phases, while no PLK4 was detected in the control IP
(Fig. 3f). Therefore, our results together suggest that KAT2A/2B
and PLK4 co-localize at centrosomes and can associate mostly
during late G1 and S phases in human cells.
KAT2-containing complexes regulate centrosome duplication.
Next, we set out to investigate the role of KAT2A/2B in the
regulation of centrosome number in human cells. We previously
reported that depletion of the ADA2a/ADA3 subunits of the
AT module of the ATAC complex results in supernumerary
centrosomes in 3T3-NIH ﬁbroblasts14, compatible with the idea
that KAT2A/2B may be negative regulators of centrosome
duplication. However, the underlying molecular mechanism
remained elusive. To investigate the hypothesis that KAT2A/2B
negatively regulates centrosome numbers through PLK4
acetylation, human U2OS cells were transfected with an
expression vector expressing human KAT2A or its catalytic
dead double point mutant (KAT2Amut)36. Forty-eight hours
after transfection, cells were ﬁxed and centrosomes were
visualized by immunoﬂuorescence using antibodies against the
pericentriolar material component g-tubulin and the centriole
component Centrin-2 (Fig. 4a,b). Whereas cells overexpressing
the wild-type (WT) version of KAT2A did not experience
alterations in centrosome number, we found that cells
overexpressing KAT2Amut had supernumerary centrosomes,
suggestive of a dominant negative effect (Fig. 4b). Moreover, we
found that shRNA-mediated depletion of KAT2A, as well as that
of ADA2a or ADA3, which are all subunits of the AT module of
ATAC complex22, led to a similar phenotype as that of cells
overexpressing KAT2Amut (Fig. 4a,b). Note that the knockdown
of ADA3 depletes the AT activity of both KAT2A- and the
KAT2B-containing ATAC complexes22. Together, these results
indicate that KAT2A/2B AT activity in the ATAC coactivator
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Figure 2 | KAT2A and KAT2B acetylate the kinase domain of PLK4. (a) Alignment of the ﬁrst 55 amino acids of human PLK4 with the corresponding
sequences from several other species. Danre, Danio rerio; Drome, Drosophila melanogaster; Human, H. sapiens; Mouse, Mus musculus. The well-conserved
acetylated K45 and K46 residues are highlighted with red dots. (b) In vitro ATassay on recombinant PLK4. Molecular weight markers are indicated on the
left in kDa. (c) PLK4 kinase domain (KinDo) was acetylated by KAT2A, KAT2Amut or KAT2B, and the acetylation sites determined after LC–MS/MS
analysis. Acetylation abundance factor (see Methods) values are depicted using the indicated colour code. (d) HEK293 cells were transfected with
expression vectors coding for only the Flag tag, Flag-tagged KAT2A or Flag-KAT2B. Western blots were probed with the indicated antibodies. (e) PLK4ac
(green) and Centrin-2 localization (red) were probed by immunoﬂuorescence. Scale bars represent 5 mm for the high-magniﬁcation view, 1 mm for the inset.
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complexes plays an essential role in restricting centrosome
duplication in human cells.
Acetylation of PLK4 stabilizes its inactive conformation.
Dynamic switching between active and inactive conformations
regulates kinases so that their inhibition can be achieved by
trapping them in their inactive state45,46. Scrutiny of the PLK4
kinase domain revealed that K45 and K46 are located at the
N-terminal extremity of a-helix B, a short helix situated
N-terminal and almost perpendicular to the main regulatory
a-helix C of the kinase (Fig. 5a,b). Thus, acetylation of K45 and
K46 residues by KAT2s could conceivably affect the structure of
the kinase domain and/or its dynamic equilibrium between
active/inactive conformations. To address these possibilities
and to understand the consequences of K45 and K46
acetylation, we carried out molecular dynamics simulations of
the kinase domain. These in silico experiments revealed that such
acetylation is expected to directly affect the H-bond network of
K45 and K46, thus suppressing their interactions with
neighbouring charged residues and weakening a few backbone–
backbone H-bonds within the N-lobe b-sheets of the kinase
domain (Fig. 5a,b).
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different cell cycle stages. Data were collected from three experiments. n4100 cells per cell cycle stage. Error bars: s.e.m. (e) Cell cycle-staged HeLa cell
extracts were prepared. The cell cycle distribution was veriﬁed by western blot. (f) Using these cell cycle-staged protein extracts IP experiments were
carried out with either anti-KAT2A antibodies (KAT2A IP) or control antibodies (mock IP). The presence of KAT2A and PLK4 in the IPs was tested by
western blot analysis (WB). M, molecular weight marker in kDa.
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The modelling uncovered also that K45/K46 acetylation might
alter the structural dynamics of the kinase domain in regions that
are somewhat distant from the acetylation site. Of particular
interest, differences were noted in interaction networks and
residue-to-residue distances, or dihedral angles, which involve
amino acids of the kinase domain important for catalytic activity.
The modelling indeed established differences in the inactive
conformation of the b1–b2 loop, which is part of the ATP-
binding site. Thus, the acetylated version of the protein adopts a
different conformation, in which van der Waals interactions are
reinforced in this loop, which may tilt the balance towards the
inactivate state. Furthermore, the most sizeable differences due to
K45/K46 acetylation are observed around the D154F155G156
(DFG) motif of the activation loop, which is central for kinase
activation by ensuring transitions between active and inactive
structures46,47. Moreover, backbone dihedral angles of residues
A153 and L157 were affected as well. Importantly, the
distribution of phi/psi angles sampled by D154 of the DFG
loop differs in the WT and acetylated simulations (Fig. 5c–f),
additionally suggesting that acetylation could stabilize the inactive
conformation of the kinase. In conclusion, the simulation data
indicate that K45/K46 acetylation would not only affect structural
networks locally, but also at more distant amino acids, which are
crucial for kinase catalytic activity. Moreover, these data indicate
that such modiﬁcations are expected to shift the dynamics of the
acetylated PLK4 towards the inactive conformation.
Acetylation of PLK4 by KAT2A/2B inhibits its kinase activity.
To test the above structural predictions, we set out to determine
the inﬂuence of acetylation on the kinase activity of the PLK4
kinase domain. Kinase assays were performed with either
unmodiﬁed or by KAT2A- or KAT2B-acetylated kinase domain
(Fig. 6a–d). Acetylation of the PLK4 kinase domain in these
experiments was tested by western blot using an anti-pan-acetyl-
lysine antibody, whereas autophosphorylation of the recombinant
kinase domain was quantiﬁed as a readout of PLK4 kinase
activity28. We found that acetylation of the PLK4 kinase domain
by either KAT2A or KAT2B signiﬁcantly reduced PLK4 kinase
domain activity (Fig. 6a–d), with the extent of inhibition inversely
correlating with the strength of acetylation (Fig. 6a–d). Thus, in
agreement with the above modelling data, acetylation of PLK4 has
an inhibitory effect on its kinase activity.
We tested KAT2A- or KAT2B-acetylation-dependent inhibi-
tion of PLK4 kinase activity using a different substrate. To this
end, we expressed and puriﬁed the crypto polo box (CPB)
domain of PLK4, another substrate of PLK4 (ref. 30). The kinase
domain was pre-acetylated by KAT2A or KAT2B in the presence
of CPB, and the phosphorylation of CPB and PLK4 then detected
by autoradiography (Fig. 6e, see 32P panel). The effect of the
acetylation on the kinase domain was also veriﬁed by using the
catalytic dead mutants of KAT2A and KAT2B (Fig. 6e and
Supplementary Fig. 2b). We found that the presence of either
KAT2A or KAT2B AT activity dampened PLK4 kinase domain
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activity as measured by CBP phosphorylation (Fig. 6e). These
results conﬁrm that acetylation of PLK4 inhibits its kinase
activity.
Next, we investigated whether lysines K45 and K46 are
important for regulating PLK4 kinase activity. K to Q replace-
ments mimic acetylation by substituting the charged lysine by a
neutral analogue bearing an amide side chain, although it has
been suggested also that this may overestimate the impact of this
post-translational modiﬁcation48. Moreover, our molecular
dynamics simulations of the PLK4 kinase domain containing
K45Q and K46Q replacements revealed that the mimic would be
imperfect in this case, since the Q side chains are signiﬁcantly
shorter than those of the acetylated K. As a result, local
perturbations of the H-bond network around the mutation
sites, both in the active and in the inactive conformations, were
found in the catalytic site of the kinase domain (Supplementary
Fig. 4c,d), in contrast to the simulations obtained with acetylated
K45/K46, which shifted the equilibrium towards the inactive
conformation (Fig. 5). As an alternative means to test whether
lysines K45 and K46 are important for regulating PLK4 kinase
activity, we generated a mutant version in which K45 and K46 are
replaced with non-acetylable arginine (R) residues. Interes-
tingly, molecular dynamics simulations suggested that these
substitutions stabilize the kinase in its inactive conformation
without inﬂuencing its general structure (Supplementary
Fig. 4a,b). In spite of the fact that the K45R/K46R mutant
cannot be acetylated, the modelling suggested that the arginine
substitutions may stabilize the kinase in its inactive conformation
similarly (although weaker) as do the acetylations of the K45 and
K46 residues in the WT kinase (Supplementary Fig. 4a,b).
Accordingly, we found that the kinase activity of the K45R/K46R
mutant kinase domain was reduced 2.5-fold when compared with
the WT (Fig. 6f,g).
Although we cannot formally exclude that the impact of the
K45R/K46R mutations might not only inﬂuence the acetylation of
K45/K46, but also impair the kinase activity irrespective of these
modiﬁcations, these results taken together indicate that in vitro
acetylation of PLK4 at positions K45 and K46, or mutation of
these residues to R45/R46, inhibits PLK4 kinase activity.
KAT2A/2B are required for proper phosphorylation of PLK4.
Next, we investigated whether KAT2A or KAT2B are necessary
for proper phosphorylation of endogenous PLK4, which provides
a read-out of PLK4 activity40. To this end, we have carried out
siRNA knockdown experiments of either KAT2A or KAT2B,
detecting PLK4 auto-phosphorylation by immunoﬂuorescence
using an antibody detecting PLK4 phosphorylated at position
Ser305 (pSer3005)40. In parallel, centrosomes were marked with
antibodies directed against g-tubulin. Cells in mitosis were
quantiﬁed for the extent of total centrosomal pSer305 signal.
Importantly, these experiments revealed that PLK4 phospho-
rylation augmented when KAT2A or KAT2B were knocked down
(Fig. 7a,b). By contrast, levels of total centrosomal PLK4 appeared
not to be altered (Supplementary Fig. 5). These results suggest
that KAT2A/2B are required for proper phosphorylation of PLK4
in human cells.
PLK4 acetylation by KAT2s prevents centrosome ampliﬁcation.
To analyse the cellular role of PLK4 acetylation in regulating
centrosome numbers, we generated full-length PLK4-GFP vectors
with either K45/K46 (WT) or K45R/K46R (double mutant). Cells
were transfected with these expression vectors and examined 48 h
thereafter by immunoﬂuorescence with antibodies against green
ﬂuorescent protein (GFP), to monitor the localization of the
fusion proteins, as well as against Centrin-2, to mark centrioles.
We noted ﬁrst that both WT and K45R/K46R mutant version
localized to centrosomes (Fig. 7c). Second, the number of
Centrin-2 foci in mitotic cells was determined as read-out of
successful centriole formation. Cells transfected with the empty
vector (control) usually harboured four centrin foci in mitosis,
with only B16% of cells having more than four (Fig. 7c,d).
As reported previously26, overexpression of WT PLK4-GFP
caused massive centriole ampliﬁcation, with B60% of mitotic
cells having more than four centrioles (Fig. 7c,d). By contrast,
overexpression of PLK4-K45R/K46R-GFP only mildly increased
the percentage of cells with more than four centrioles (B30% of
cells; Fig. 7c,d and Supplementary Fig. 6a). Moreover, the
centriole ampliﬁcation provoked by overexpression of WT
PLK4-GFP was dampened by the concomitant overexpression
of KAT2A or KAT2B (Supplementary Fig. 6b). In addition, as
anticipated, removal of PLK4 activity using either siRNAs or the
small molecule centrinone also prevented centriole formation in
cells that were depleted of KAT2A or KAT2B in addition
(Supplementary Fig. 6c). Taken together, these results demon-
strate that the combined point mutations in the kinase domain
severely impair PLK4 function.
Next, endogenous PLK4 was depleted using siRNAs targeting
the 30-untranslated region of the genomic PLK4 locus, a region
that is absent from the two PLK4-GFP (WT and double mutant)
expression vectors. Depletion of endogenous PLK4 by siRNA
caused centriole underduplication, as evidenced by the fact that
B30% of cells contained less than three centrioles during mitosis
(Fig. 7e). Expression of WT PLK4-GFP rescued this phenotype.
In contrast, expression of PLK4-GFP[K45R/K46R] did not
(Fig. 7e), further demonstrating that this mutant is inactive.
Thus, our in vitro and in vivo experiments concur to suggest that
AT activities of KAT2A/2B and acetylation of K45/46 in PLK4 are
necessary to restrict the number of centrosomes.
Discussion
The role for acetylation in the regulation of several cellular
processes is well documented. Moreover, the widespread nature
of protein acetylation and the large number of identiﬁed
acetylated proteins (more than 6,000)10 raised questions about
the role of individual KATs and their importance in regulating
different cellular functions. Here we describe the identiﬁcation of
about 400 proteins acetylated by KAT2A and KAT2B. Gene
ontology analyses indicated that these acetylated non-histone
proteins play a role in well-deﬁned cellular functions, such as
chromatin remodelling, transcriptional regulation, DNA
replication, DNA repair, cell death and cell cycle progression.
KAT2A and 2B were already suggested to be involved in several
of these processes (see Introduction). Interestingly, here we
identiﬁed acetylated proteins involved in novel pathways,
such as actin-mediated cell contraction, protein transport,
phosphorylation and regulation of centrosome duplication
(Fig. 1 and Supplementary Data 1), suggesting that by
acetylating these non-histone proteins KAT2A/2B can also
regulate their function. It is tempting to speculate that the
coordinated acetylation by KAT2A/2B of histones and
non-histone proteins at regulatory genomic locations could be
linked. Indeed, by loosening the chromatin at their site of action,
KAT2A/2B could facilitate the recruitment of factors involved in
the chromatin-associated processes mentioned above and
modulate their action by further acetylation.
Other kinases besides PLK4 may be acetylated by KAT2A/2B,
including CDK2 (ref. 49), CDK5 (ref. 50) and CDK9 (ref. 51).
However, the mechanism of kinase inhibition is different in those
cases when compared with PLK4. Indeed, KAT2A/2B acetylate
CDK2, CDK5 and CDK9 at the ATP-binding sites (located at
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positions K33 of human CDK2 and CDK5, and at position K48 of
human CDK9 (Supplementary Fig. 7). The impact of acetylation
on the ATP-binding site of CDK5 has not been studied. However,
mutations of the ATP-binding sites into non-acetylable residues
(R) in CDK2 and CDK9 inhibited kinase activity by preventing
ATP binding49,51. Importantly, our results suggest a different
mechanism through which acetylation inhibits kinase activity in
the case of PLK4. Indeed, our molecular modelling experiments
indicate that acetylation not only affects structural networks near
the acetylated lysines, but also at more distant amino acids, which
are crucial for kinase catalytic activity (such as the DFG motif).
Importantly, in addition, the simulations suggest that these
modiﬁcations shift the dynamic equilibrium of the acetylated
PLK4 towards its inactive conformation. Thus, our data suggest
that KAT2A/2B-dependent acetylation of PLK4 in the kinase
domain is required to limit kinase activity of PLK4, perhaps
primarily during S phase after PLK4 has acted to initiate centriole
formation, to avoid subsequent rounds of centriole formation
and centrosome overampliﬁcation. KAT2A/2B are therefore
important for the maintenance of genomic stability.
The serine/threonine PLK4 is a pivotal regulator of centrosome
duplication. Identiﬁed PLK4 substrates include Cep152 (ref. 52)
and STIL53, the modiﬁcations of which are both critical for the
onset of procentriole assembly52,53 In this study, we have
uncovered that centrosome duplication in mammalian cells is
modulated by acetylation of PLK4. Our data indicate that
acetylation negatively regulates PLK4 kinase activity and thus
prevents centrosome overampliﬁcation. This is in line with
previous reports showing that lysine acetylation is detected at
centrosomes by immunoﬂuorescence using a pan-acetyl lysine
antibody54. While we have described a role for the
acetyltransferases KAT2A/2B in the regulation of centriole
numbers, other studies have reported roles for lysine
deacetylases (KDACs) in regulating centrosome function. For
example, it was shown that KDAC8 depletion enhances
centrosome splitting in human cells, while KDAC1 depletion or
treatment with the KDAC inhibitor trichostatin A had opposite
effects, with reduced centrosome splitting55. Moreover, it has
been proposed that proteins involved in centrosome cohesion
would be acetylated and substrates of these KDACs. This
suggestion was further supported by localization studies
showing that several KDACs, including KDAC1, localize at
centrosomes54. The above ﬁndings notwithstanding, the exact
mechanism for the regulation of centrosome architecture and/or
numbers by KDACs is unclear.
The activity and stability of PLK4 have to be tightly
controlled to avoid severe defects, such as genomic instabil-
ity23,56. The mechanisms governing PLK4 protein stability have
been well studied, with PLK4 regulating its own stability
by autophosphorylation, which triggers ubiquitin-mediated
proteasomal degradation (reviewed in refs 28–30). However,
the mechanisms controlling PLK4 kinase activity have
remained elusive. In this study, we show that lysine
acetylation regulates PLK4 kinase activity. It is conceivable
that degradation of PLK4 and acetylation-dependent inhibition
of kinase activity act in concert to achieve a tight control of
centrosome duplication. In the future, it will be interesting to
investigate whether these PTMs act independently or in a
coordinated fashion during cell cycle progression to accurately
regulate PLK4 function.
Methods
Plasmids. The bacterial expression vector petHis30a-HisPLK4 KinDo was a
generous gift from A. Holland29. The mammalian expression vector pcDNA3-
FlagPLK4 has been described57. The bacterial expression vector petHis15b-CPB
was created by insertion of the PLK4 cDNA fragment aa 635–878 containing the
CPB domain into pet15bHis. The PCR fragment was ampliﬁed with primers
50-AGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGAAGTTCTTCAGAT
ATCTAGTGAT-30and 50-TCGGGCTTTGTTAGCAGCCGGATCCTCATTTTAG
ACTATTAGAAGAGA-30 , and then cloned by recombination into the
NdeI/BamHI site of the pET15b vector. The baculovirus expressing Flag-tagged
KAT2A (GCN5) and the expression vector for Flag-tagged KAT2A (GCN5)
catalytic mutant in which E575 and D615 were both replaced by alanine were
described in ref. 14. The Flag-tagged KAT2B (PCAF) baculovirus expression vector
was kindly provided by N. Rochel-Guiberteau. The baculovirus expression vector
for Flag-tagged KAT2B (PCAF) catalytic mutant in which E570 and D610 were
both replaced by alanines was made by insertion of a PCR fragment containing the
mutations. The DNA was ampliﬁed with primers 50-GGAAGATCTCCACCATG
GATTACAAGGATGACGACGATAAGCCCGGGTCCGAGGCTGGCGGGGCC
GGGCCG-30 and 50-CGCGAATTCTCACTTGTCAATTAATCCAGCTTCCTT-30 ,
digested by BglII and EcoRI, and ligated into pVL1393 baculovirus expression
vector digested with BglII and EcoRI. The mammalian expression vector
pcDNA3-Flag and pcDNA3-FlagKAT2A have been described in ref. 14. The
mammalian expression vector pCDNA3-FlagKAT2B was provided by the Addgene
plasmid repository.
K to R point mutations at K45 and K46 in the PLK4 kinase domain were
introduced within the petHis30a-HisPLK4KinDo or the hPLK4-EGFP-pCDNA
plasmids by PCR direct-site mutagenesis using the following primers: 50-GCAAT
CAAAATGATAGATCGACGAGCCATGTACAAAGCAGGA-30 forward; and
50-TCCTGCTTTGTACATGGCTCGTCGATCTATCATTTTGATTGC-30 reverse.
The primers were used for ampliﬁcation of the template DNA. After 15 cycles
using Pfu DNA polymerase, the product was treated with DpnI and then
transformed directly into Escherichia coli XL1 Blue. Miniprep plasmid DNA was
used to sequence and control the point mutations.
Antibodies. Antibodies against KAT2A (GCN5; mouse monoclonal antibody
(mAb) 2GC2C11, dilution 1:1,00058; or mAb 5GC2A6 (ref. 14), dilution 1:1,000),
KAT2B (PCAF; antibody, Santa Cruz sc-13124; sc-8999; dilution 1:500 for
immunoﬂuorescence studies), rabbit acetyl histone H3 (Milipore 06-599, dilution
1:2,000), rabbit pan acetyl-lysine rabbit polyclonal (Cell Signaling, #9441, dilution
1:1,000), g-tubulin (mAb, Sigma-Aldrich GTU-88; dilution 1:1,000), rabbit
polyclonal g-tubulin (Sigma-Aldrich, T 5192, dilution 1:1,000), rabbit monoclonal
PLK4 (Abcam #Ab109008, dilution 1:500), Centrin-2 (mAb, Merck-Millipore
20H5; dilution 1:4,000), rabbit polyclonal PLK4-pS305P ((ref. 40), dilution 1:500,
gift from M. Bornens, Institut Curie, Paris, France), rabbit GFP (dilution 1:500, gift
from V. Simanis, Swiss Federal Institute of Technology, Lausanne, Switzerland),
HsSAS-6 (mAb, Santa Cruz sc-81431; dilution 1:500), rabbit polyclonal CP110
(ProteinTech, 12780–1-AP; dilution 1:1,000), Flag (mAb, Sigma-Aldrich F1804,
clone M2; dilution 1:1,000), Flag M2 afﬁnity gel, A2220 (Sigma-Aldrich), rabbit
CyclinE (Santa-Cruz sc-481, M-20; dilution 1:1,000), Plk1 (mAb, Sigma-Aldrich
36-298 #P6123; dilution 1:1,000) have been described previously or have been
purchased as indicated.
To generate polyclonal antibodies against PLK4ac, a peptide acetylated at
positions K45 and K46 was synthesized: from aa 34 (TGLEVAIKMIDKacKacAM
YKAGMVDQR-C) to aa 56. The same peptide without the acetylated residues was
also synthetized. The acetylated peptide was coupled to ovalbumin carrier protein
and used for immunization of rabbits at the IGBMC rabbit facility. Collected sera
were ﬁrst puriﬁed on a SulfoLink column (Pierce) to which the peptide that did not
contain the acetylated residue has been conjugated through its C-terminal cysteine.
Afﬁnity columns were prepared as speciﬁed by the manufacturer. After having
passed the sera through the non-acetylated peptide-containing column ﬁve times,
the ﬂow-through fraction was further puriﬁed on an afﬁnity column to which the
acetylated peptide had been conjugated. Bound proteins were extensively washed,
antibodies were eluted with Tris-Glycine (pH 2.8) buffer, neutralized immediately
with 2M Tris-HCl (pH 8.8), dialysed and kept at  20 C. Enzyme-linked
immunosorbent assay tests were carried out using standard protocols. The rabbit
PLK4ac antibody was used at a 1/500 or at 1/5,000 dilutions in the different
applications (as indicated).
Inducible HeLa shRNA cell lines. Generation of the inducible HeLa cells
harbouring shRNA directed either against GCN5/KAT2A (target sequences:
50-CGTGCTGTCACCTCGAATGA-30) or GL2 luciferase as control (target
sequences: 50-CCTTACGCTGAGTACTTCGA-30) were described previously
in ref. 14.
Cell synchronization experiments. Cell synchronization experiments were
performed by double thymidine block using HeLa Kyoto cells as described in
ref. 59. Brieﬂy, cells were ﬁrst blocked in G1/S with 2mM thymidine treatment for
18 h, released in fresh media for 9 h and then blocked again in G1/S with 2mM
thymidine treatment for 16 h. After double thymidine block, cells were release in
fresh media and collected at 0, 2, 4, 6, 8, 10, 12 and 14 h thereafter. Mitotic shake
off was used to synchronize cells in G2/M60,61.
Cell extracts and protein puriﬁcation. For protein puriﬁcation from baculovirus/
insect cells expression system: SF9 cells were infected with baculoviruses expressing
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Flag-tagged hKAT2A, hKATAmut, hKAT2B or hKAT2Bmut. Forty-eight hours
post infection, cells were collected by centrifugation at 1,500 r.p.m. at 4 C, washed
into 1 phosphate buffer saline solution (PBS1 ) and lysed into 0.4M KCl,
15mM Tris-HCl (pH 8.0), 20% glycerol, 5mM MgCl2, 0.4% NP-40, 1 protease
inhibitor cocktail (Roche) and 1mM dithiothreitol (DTT). After 10min of
centrifugation at 8,000 r.p.m. at 4 C the supernatant containing whole-cell protein
extracts was collected and incubated with Flag-M2 for IP of Flag-tagged proteins.
After 1 h of incubation at 4 C on a rotating wheel, beads were washed twice with
IP buffer (25mM Tris-HCl (pH 8.0), 10% glycerol, 5mM MgCl2, 0.1% NP-40, 1
protease inhibitor cocktail and 1mM DTT) containing 0.5M KCl and twice with
an IP buffer containing 0.1M KCl, before elution with a Flag tag peptide
DYKDDDDK at 2mgml 1 ﬁnal concentration dissolved in 0.1M KCl IP buffer.
Wild-type, mutant recombinant PLK4 kinase domain and recombinant PLK4 CPB
domain were puriﬁed from E. coli (strain Rosetta DE3) as described in ref. 29. To
generate whole-cell protein extracts of HeLa cells knocked down for KAT2A and
KAT2B, cells were lysed with a buffer containing 0.4M KCl, 20% glycerol, 20mM
Tris-HCl (pH 7.5), 1 protease inhibitor cocktail (PIC) and 2mM DTT, in the
presence of 5mM sodium butyrate (NaB) to preserve acetylated sites, after three
cycles of freezing and thawing steps in liquid N2. After centrifugation for 30min at
14,000 r.p.m. at 4 C, supernatants containing soluble whole-cell protein extracts
were collected for further proteomic analyses. To generate whole-cell protein
extracts from HEK293 cells overexpressing Flag-KAT2A or Flag-KAT2B, cells were
lysed in a buffer containing 150mM NaCl, 50mM Tris-HCl, 2mM EDTA, 0.5%
NP-40, benzonase (125Uml 1), 2mM MgCl2, 1mM DTT, 1 protease inhibitor
cocktail (Sigma), 5mM NaB as a deacetylase inhibitor and 20mM sodium ﬂuoride,
20mM b-glycerophosphate and 1mM sodium orthovanadate as phosphatase
inhibitors. After centrifugation for 30min at 13,200 r.p.m. at 4 C, supernatants
containing WCL were collected.
For IP of endogenous KAT2A, synchronized, HeLa Kyoto cells were lysed in a
buffer containing 150mM NaCl, 50mM Tris-HCl, 2mM EDTA, 0.5% NP-40,
benzonase (125U ml 1), 2mM MgCl2, 1mM DTT, 1 protease inhibitor cocktail
(Sigma), 5mM NaB as a deacetylase inhibitor and 20mM sodium ﬂuoride, 20mM
b-glycerophosphate and 1mM sodium orthovanadate as phosphatase inhibitors.
After centrifugation for 30min at 13,200 r.p.m. at 4 C, supernatant containing
WCL was collected and incubated for 1 h on a rotating wheel at 4 C, with
anti-KAT2A antibodies crosslinked to protein-G agarose magnetic beads. After
washing beads with a buffer containing 150mM NaCl, 50mM Tris-HCl (pH 8.0),
2mM EDTA, 2mM MgCl2, 0.1% NP-40, 1mM DTT, 1 ﬁnal protease inhibitor
cocktail, 5mM NaB, 20mM sodium ﬂuoride, 20mM b-glycerophosphate and
1mM sodium orthovanadate, KAT2A immunoprecipitated proteins were eluted
from beads in lithium dodecyl sulphate buffer supplemented with 100mM DTT for
10min incubation at 85 C before SDS–PAGE and western blot analysis. Mock IP
was performed as described above, but using protein-G agarose beads only.
Western blot assays. For western blot analyses, protein samples were separated
by SDS–PAGE and transferred onto nitrocellulose membrane (Whatman),
blocked with 5% skimmed milk in PBS and incubated with primary antibodies as
described above. The membranes were then incubated with anti-mouse or -rabbit
horseradish peroxidase-linked secondary antibodies (at 1:10,000 dilution) and
proteins detected by chemiluminescence using Detection Reagents 1 and 2
(Thermo Scientiﬁc).
Uncropped scans of the gels and blots shown in Figs 1a, 2, 3 and 6 are provided
as Supplementary Fig. 8
ATassays. AT assays on recombinant proteins were performed by incubating, for
1 h at 30 C, His-tagged puriﬁed PLK4 kinase domain with puriﬁed recombinant
Flag-tagged KAT2A, Flag-KAT2Amut, Flag-KAT2B or Flag-KAT2Bmut in the
presence of cold acetylcoenzyme A. The reaction buffer contained 50mM M Tris-
HCl (pH 8.0), 10% glycerol, 100mM EDTA, 50m M KCl, 0.1M NaB, 1 protease
inhibitor cocktail (Roche, France) and 5mM DTT. Reactions were incubated for
1 h at 30 C, stopped by adding Laemmli buffer with 10% b-mercaptoethanol,
boiled for 5min and loaded on acrylamide gels. The protein mixtures were resolved
by SDS–PAGE and analysed by western blot using anti pan-acetyl lysine antibodies
after Ponceau staining of the membrane to reveal overall protein distribution.
Phosphorylation assays using the kinase domain of PLK4. Kinase assays were
performed on recombinant PLK4 kinase domain or on the CPB of PLK4 as
described in ref. 29. The level of phosphorylation activity of the kinase domain
(in the presence of [32Pg]-ATP) was quantiﬁed either by autoradiography or by
direct counting of the radioactive signal.
Cell culture and plasmid transfection experiments. HEK293T and HeLa Kyoto
cells were grown in Dulbecco’s modiﬁed medium (DMEM) with 1 g l 1 glucose,
supplemented with10% fetal calf serum and 100 units per ml penicillinþ 100
mgml 1 streptomycin (Gibco). U2OS cells were obtained from the EACC and
maintained in DMEM (Gibco) containing 1 g l 1 glucose, supplemented with 10%
fetal bovine serum and gentamycin 40 mgml 1.
DNA and siRNA transfection were performed using Lipofectamine 2000
(Thermo Scientiﬁc) or RNAiMax and OptiMEM (Invitrogen), respectively,
according to the manufacturers’ protocols, and cells were analysed 48–72 h after
siRNA treatment. shRNA (for Ada2a, Ada3 and GCN5) and cDNA (for Ada2a,
Ada3, GCN5 WT or mutated on the HAT domain) have been previously described
in ref. 14. Simultaneous knockdown and overexpression: endogenous PLK4 was
depleted using a Stealth siRNA (Invitrogen) targeting the 30-untranslated region of
PLK4 (5-AATAACTTACCAGTAAACTCACTTT-3). Stealth siRNA negative
control LO GC (Invitrogen) was used as a control. Twenty-four hours after siPLK4
transfection, cells were transfected with plasmids encoding WT or K45R/K46R
PLK4. Forty-eight hours after DNA transfection, cells were ﬁxed and stained.
To carry out KAT2A (GCN5) and/or KAT2B (PCAF) knockdown,
Lipofectamine 2000 was used following the supplier’s instructions. The siRNAs
used were ON-Targetplus SMARTpools from Dharmacon (Thermo Fischer
Scientiﬁc): GCN5L2 (KAT2A), L-009722-00; PCAF (KAT2B), L-005055-00; and
non-targeting pool, D001810-10-05, as negative control. A unit of 60 nM siRNA
was used in all knockdown conditions. Cells were treated with siRNAs for 72 h
before collection.
Centrinone (PLK4 inhibitor) treatments were performed as described in ref. 62.
Twenty-four hours after siRNA transfection, cells were treated for 24 h with
centrinone at a ﬁnal concentration of 125 nM.
Immunoﬂuorescence and microscopy for human cells. U2OS cells grown on
glass coverslips were ﬁxed for 7min in  20 C methanol, washed in PBS and
blocked in 1% bovine serum albumin and 0.05% Tween-20 in PBS. Cells were
incubated for 2 h at room temperature with primary antibodies, washed three times
for 10min in PBST (0.05% Tween-20 in PBS), incubated for 45min at room
temperature with secondary antibodies, stained with B1 mgml 1 Hoechst 33258,
washed three times in PBST and mounted. Primary antibodies are described above.
Secondary antibodies were 1:1,000 goat anti-rabbit coupled to Alexa 488 and
1:1,000 goat anti-mouse coupled to Alexa 568. Imaging was done on a Zeiss
LSM710 confocal microscope. Optical sections were acquired every 0.12 mm, and
planes containing centrioles were projected together. Images were processed using
ImageJ, preserving relative image intensities within a series.
Levels of PLK4-pS305 at the centrosome were quantiﬁed as follows. Cells were
ﬁxed with methanol, stained for PLK4-pS305 and g-tubulin to localize
centrosomes. The total PLK4-pS305 signal was determined within a circular region
of 20 px diameter (B1 mm) centred on the g-tubulin focus. After subtraction of the
background present outside cells, the total centrosomal intensity per cell was
determined as the sum of all centrosomal intensities.
Homology modelling. Crystallographic structures of PLK4 were taken from the
Protein Data Bank (PDB accession codes: 3COK, 4JXF) for both the active and
inactive forms of the protein63. Owing to a lack of electron density, no structure
was resolved for residues in the activation loop, and so a structure was constructed
for this segment using the Modeller programme64. In the active form, segments
158–189 and 212–226 were modelled using the structures of PLK2 and PLK3 as
starting templates (accession codes: 4i6h and 4b6l, respectively). In the inactive
form, residues 165–191 and 211–216 were modelled using an Aurora Kinase
structure (accession code 4J8M) as a starting template. This latter structure was
chosen because of its similarity with the fold of the N-terminal part of the
activation loop of PLK4 (in the inactive structure of PLK4, see PDB ID 4JXF).
In the 4JXF structure the DFG is in an inactive conformation65.
For each structure (active and inactive), 1,000 homology models were generated
using the automodel module of Modeller64 and their quality was evaluated using
the DOPE score66.
System set-up. The histidine protonation states were obtained using a protocol
based on free energy perturbation calculations, as described in ref. 67. Except
for histidines, all amino acids were built in their standard protonation states,
as were the N- and C-termini of the kinase (NH3þ and COO , respectively).
Coordinates of ATP in the active form were obtained by replacing nitrogen by
oxygen in the ANP ligand of structure 3cok. Hydrogen atoms were added using the
Hbuild module68 of the CHARMM programme69. The system was then subjected
to an energy minimization, and solvated in an 80Å pre-equilibrated box of TIP3P
water molecules. Neutralization was achieved by the random addition of one to
eight chloride counter-ions.
Molecular dynamics. For each structure (active and inactive), we performed four
replicate simulations of 50 ns of both the WT and the doubly acetylated form
(K45acK46ac). In addition, we performed four replicate simulations of 50 ns for the
active and inactive (K45RK46R) mutants. The total cumulated simulation time for
the ensemble of the study is thus 1.2 ms. The simulations were performed at a
temperature of 298.15 K in the NPT ensemble and were run with the NAMD
programme70 using the CHARMM36 force ﬁeld71. For the acetylated lysines,
parameters from ref. 72 were used. Non-bonded interactions were truncated at a
cutoff of 14 Å, using a switch function for van der Waals, and a shift function for
electrostatics. Long-range electrostatic interactions were evaluated using the
particle mesh Ewald algorithm. We used a 2fs integration step. The SHAKE
algorithm was used to constrain bonds with hydrogen atoms.
Analysis. To assess the degree of conformational change undergone by the
proteins in the molecular dynamics simulations, we calculated the root mean
squared difference in conformation. The root mean squared difference plots show
that the trajectories stabilized towards the 20 ns mark of the simulations, so all
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13227 ARTICLE
NATURE COMMUNICATIONS | 7:13227 | DOI: 10.1038/ncomms13227 |www.nature.com/naturecommunications 13
analyses were carried out on the 20–50 ns window. We calculated the percentage of
existence (occupancy) of the internal H-bonds of the kinase, as well as those
mediated by the ATP in the active form using the COOR HBOND module of the
CHARMM programme69. Pairwise distances between the backbone and the side
chain of each residue were calculated by using the distance between the Ca atom
and the centre of mass of the respective side chain. This analysis was performed to
detect subtle and local modiﬁcations of conformation. The analysis protocol relies
on the detection of reproducible differences between two sets of simulations: WT
versus variant. All differences mentioned in the text will thus correspond to
reproducible differences, unless explicitly stated.
Mass spectrometry analyses. For MudPIT analyses protein mixtures were
denatured with urea, reduced, alkylated and digested with endoproteinase Lys-C
(Roche), followed by modiﬁed trypsin digestion (Promega). Peptide mixtures were
loaded onto a triphasic 100 mm diameter fused silica microcapillary column, packed
with C18 reverse phase (Aqua, Phenomenex) and strong cation exchange
(Partisphere SCX, Whatman) particles. Loaded microcapillary columns were
placed in-line with a Quaternary Dionex Ultimate 3000 HPLC pump and a LTQ
Velos linear ion trap mass spectrometer equipped with a nano-liquid chromato-
graphy (LC) electrospray ionization source (ThermoFischerScientiﬁc). A fully
automated 12-step MudPIT run was performed as described73 during which each
full MS scan (from 300 to 1,700m/z range) was followed by 20 MS/MS events using
data-dependent acquisition. Proteins were identiﬁed by database searching using
SEQUEST74 within Proteome Discoverer 1.3. Tandem mass spectra were searched
against a non-redundant protein sequence database for Homo sapiens containing
20,276 protein sequence entries (Uniprot release from 2010–09). Cysteine residues
were considered to be fully carbamidomethylated (þ 57Da statically added),
methionine to be oxidized (þ 16Da dynamically added) and lysine to be acetylated
(þ 42Da dynamically added). Three missed cleavages were permitted. Peptide
mass tolerance was set at 2.5 and 0.8 Da on the precursor and fragment ions,
respectively. Tandem mass spectra were ﬁltered with XCorr values equal to
1.5 (þ 1), 2.5 (þ 2), 3.0 (þ 3) and 3.2 (4þ 3). Only peptides with a minimum
length of seven residues and maximum deltaCn values of 0.3 were retained. Tryptic
peptides containing C-terminal acetylated lysines were rejected, leading to a false
discovery rate below 5%.
The LC/MS–MS analysis on the OrbiTrap ELITE were performed as follows:
digested samples were analysed using an Ultimate 3000 nano-RSLC (Thermo
Scientiﬁc, San Jose California) coupled in line with an LTQ-Orbitrap ELITE
mass spectrometer via a nano-electrospray ionization source (Thermo Scientiﬁc, San
Jose California). Peptide mixtures were loaded on a C18 Acclaim PepMap100
trap-column (75mm ID 2 cm, 3mm, 100Å, Thermo Fisher Scientiﬁc) for 3.5min at
5ml min 1 with 2% acetonitrile (ACN) and 0.1% formic acid (FA) in H2O, and then
separated on a C18 Accucore nano-column (75mm internal diameter (ID) 50 cm,
2.6mm, 150Å, Thermo Fisher Scientiﬁc) with a 120min linear gradient from 5 to
50% buffer B (A, 0.1% formic acid (FA) in H2O; B, 80% acetonitrile (acetonitrile
(ACN)) and 0.08% FA in H2O) followed with 10min at 99% B. The total duration
was set to 150min at a ﬂow rate of 200 nlmin 1. The temperature was kept constant
at 40 C. Peptides were analysed by Top 10-CID-HCD (collision induced
dissociation and high-energy collisional dissociation) data-dependent MS. Tandem
mass spectra were searched using SEQUEST HT within Proteome Discoverer 1.4,
against a non-redundant protein sequence database for H. sapiens containing 27,858
protein sequence entries (Uniprot, release 2014–11). Cysteine residues were
considered to be fully carbamidomethylated (þ 57Da statically added), methionine
considered to be oxidized (þ 16Da dynamically added) and lysine considered to be
acetylated (þ 42Da dynamically added), and two missed cleavages were permitted.
Peptide mass tolerance was set at 7 p.p.m. and 0.5(CID)/0.02(HCD) Da on the
precursor and fragment ions, respectively. The minimum peptide length required
was six residues. Proteins with at least two peptides were considered identiﬁed. The
protein identiﬁcation list was ﬁltered at a false discovery rate below 1%.
To identify KAT2A/B-dependent acetylated proteins, candidates were
considered as potential targets if they lost acetylation on KAT2A/B knockdown.
To identify these protein targets, the pool of acetylated peptides identiﬁed after
tandem MS analyses in ﬁve independent control samples (acetylome WT) was
compared with the pool of acetylated peptides identiﬁed after tandem MS analysis
in three independent replicates analyses of KAT2A/2B knocked down cells
(acetylome KAT2 KD) Proteins were considered as potential KAT2A/B acetylated
targets if they were absent in the three replicates acetylome KAT2 KD analyses and
present in at least three of the ﬁve replicates of the WT acetylome.
Acetylation abundance factors were calculated as follows: PLK4 acetylated
peptides speciﬁcally identiﬁed in KAT2A, KAT2B and KAT2A mutant conditions
were extracted and compared. Spectral counts for similar acetylated peptides
identiﬁed across these three conditions were divided by the total PLK4 spectral
counts identiﬁed in each condition, to normalize for experimental variation
encountered between independent runs. This calculation was performed for each
acetylated peptide identiﬁed, and normalized values were then summed up to
deﬁne the acetylation abundance factor of PLK4 in each condition tested.
Bioinformatic analyses. The gene ontology term analysis of the 398 KAT2A/B
targets was performed in Manteia34. Venn diagrams were generated using BioVenn
http://www.cmbi.ru.nl/cdd/biovenn/. The sequence logo was generated with
Weblogo 3.0 (http://weblogo.threeplusone.com/create.cgi). Sequence logos are a
graphical representation of an amino-acid multiple sequence alignment. Each logo
consists of stacks of symbols, one stack for each position in the sequence. In all,
2,501 distinct ‘Ks’ from the list of 398 proteins were used in this analysis with the
10 aa upstream and 10 aa downstream. The K itself is not shown in these logos.
A random selection of 5,243 sequences (K in the middle, 21 aa length, 0.05% of the
total K) from the total human proteins was used for the comparison. The overall
height of the stack indicates the sequence conservation at that position, while the
height of symbols within the stack indicates the relative frequency of each amino or
nucleic acid at that position. The PLK4 multiple protein sequence alignment was
performed in ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2). The output
ALN ﬁle was further processed with BoxShade (http://www.ch.embnet.org/
software/BOX_form.html).
Data availability. The MS proteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE75 partner repository with the dataset
identiﬁer PXD004669. The additional data that support the ﬁndings of this study
are available from the corresponding authors on request.
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